M
Murray Baron
Researcher at Jewish General Hospital
Publications - 307
Citations - 16253
Murray Baron is an academic researcher from Jewish General Hospital. The author has contributed to research in topics: Medicine & Scleroderma. The author has an hindex of 56, co-authored 288 publications receiving 13421 citations. Previous affiliations of Murray Baron include University of Western Ontario & McGill University.
Papers
More filters
Journal ArticleDOI
2013 classification criteria for systemic sclerosis: An american college of rheumatology/European league against rheumatism collaborative initiative
Frank H J van den Hoogen,Dinesh Khanna,Jaap Fransen,Sindhu R Johnson,Murray Baron,Alan Tyndall,Marco Matucci-Cerinic,Raymond P. Naden,Thomas A. Medsger,Patricia Carreira,Gabriela Riemekasten,Philip J. Clements,Christopher P. Denton,Oliver Distler,Yannick Allanore,Daniel E. Furst,Armando Gabrielli,Maureen D. Mayes,Jacob M van Laar,James R. Seibold,László Czirják,Virginia D. Steen,Murat Inanc,Otylia Kowal-Bielecka,Ulf Müller-Ladner,Gabriele Valentini,Douglas J. Veale,Madelon C. Vonk,Ulrich A Walker,Lorinda Chung,David H. Collier,David H. Collier,Mary Ellen Csuka,Barri J. Fessler,Serena Guiducci,Ariane L. Herrick,Vivien Hsu,Sergio A. Jimenez,Bashar Kahaleh,Bashar Kahaleh,Peter A. Merkel,Stanislav Sierakowski,Richard M. Silver,Robert W. Simms,Robert W. Simms,John Varga,Janet E. Pope +46 more
TL;DR: The ACR/EULAR classification criteria for SSc performed better than the 1980 ACR criteria and should allow for more patients to be classified correctly as having the disease.
Journal ArticleDOI
2013 classification criteria for systemic sclerosis: an American college of rheumatology/European league against rheumatism collaborative initiative
Frank H J van den Hoogen,Dinesh Khanna,Jaap Fransen,Sindhu R Johnson,Murray Baron,Alan Tyndall,Marco Matucci-Cerinic,Raymond P. Naden,Thomas A. Medsger,Patricia Carreira,Gabriela Riemekasten,Philip J. Clements,Christopher P. Denton,Oliver Distler,Yannick Allanore,Daniel E. Furst,Armando Gabrielli,Maureen D. Mayes,Jacob M van Laar,James R. Seibold,László Czirják,Virginia D. Steen,Murat Inanc,Otylia Kowal-Bielecka,Ulf Müller-Ladner,Gabriele Valentini,Douglas J. Veale,Madelon C. Vonk,Ulrich A Walker,Lorinda Chung,David H. Collier,David H. Collier,Mary Ellen Csuka,Barri J. Fessler,Serena Guiducci,Ariane L. Herrick,Ariane L. Herrick,Vivien Hsu,Sergio A. Jimenez,Bashar Kahaleh,Peter A. Merkel,Peter A. Merkel,Stanislav Sierakowski,Richard M. Silver,Robert W. Simms,John Varga,Janet E. Pope +46 more
TL;DR: The ACR/EULAR classification criteria for SSc performed better than the 1980 ACR criteria and should allow for more patients to be classified correctly as having the disease.
Journal ArticleDOI
Safety and efficacy of subcutaneous tocilizumab in adults with systemic sclerosis (faSScinate): a phase 2, randomised, controlled trial
Dinesh Khanna,Christopher P. Denton,Angelika Jahreis,Jacob M van Laar,Tracy M. Frech,Marina E Anderson,Murray Baron,Lorinda Chung,Gerhard Fierlbeck,Santhanam Lakshminarayanan,Yannick Allanore,Janet E. Pope,Gabriela Riemekasten,Virginia D. Steen,Ulf Müller-Ladner,Robert Lafyatis,Giuseppina Stifano,Helen Spotswood,Haiyin Chen-Harris,Sebastian Dziadek,Alyssa Morimoto,Thierry Sornasse,Jeffrey Siegel,Daniel E. Furst +23 more
TL;DR: Tocilizumab was not associated with a significant reduction in skin thickening and should be investigated in a phase 3 trial before definitive conclusions can be made about its risks and benefits.
Journal ArticleDOI
A randomized, controlled trial of methotrexate versus placebo in early diffuse scleroderma
Janet E. Pope,Nicholas Bellamy,James R. Seibold,Murray Baron,Michael H. Ellman,Simon Carette,C. Douglas Smith,Ian M. Chalmers,Paul Hong,David P. O'Hanlon,Elzbieta Kaminska,Janet Markland,J Sibley,Luis J. Catoggio,Daniel E. Furst +14 more
TL;DR: Although results of this trial demonstrated a trend in favor of MTX versus placebo in the treatment of early diffuse SSc, the between-group differences were small and the power to rule out false-negative results was only 50%.
Journal ArticleDOI
Comparison of amitriptyline, cyclobenzaprine, and placebo in the treatment of fibromyalgia
Simon Carette,Simon Carette,Mary J. Bell,W. John Reynolds,W. John Reynolds,Boulos Haraoui,Boulos Haraoui,Glenn A. McCain,Vivian P. Bykerk,Steven M. Edworthy,Steven M. Edworthy,Murray Baron,Murray Baron,Barry E. Koehler,Adel G. Fam,Nicholas Bellamy,Chantal Guimont,Chantal Guimont +17 more
TL;DR: The data confirm the short-term efficacy of amitriptyline and cyclobenzaprine in a small percentage of patients with fibromyalgia and predictors of response to these drugs could not be determined.